Scalper1 News
The FDA approved Medtronic’s (MDT) CoreValve artificial heart valve Friday, well ahead of its April 1 deadline, sending shares of competitor Edwards Lifesciences (EW) tumbling on the stock market today. The CoreValve is a transcatheter aortic valve, approved to treat aortic stenosis in patients too frail for open-heart surgery. It’s similar to Edwards’ Sapien, which had the U.S. market to itself after it was approved in 2012, though the two share Scalper1 News
Scalper1 News